Free Trial
NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

Innate Pharma logo
$2.02 -0.12 (-5.37%)
As of 01:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Innate Pharma Stock (NASDAQ:IPHA)

Key Stats

Today's Range
$2.17
$2.18
50-Day Range
$1.70
$2.20
52-Week Range
$1.29
$3.51
Volume
1,165 shs
Average Volume
109,700 shs
Market Capitalization
$186.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

Innate Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

IPHA MarketRank™: 

Innate Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 411th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innate Pharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Innate Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Innate Pharma's stock forecast and price target.
  • Percentage of Shares Shorted

    0.06% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 14.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Innate Pharma does not currently pay a dividend.

  • Dividend Growth

    Innate Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.06% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 14.33%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Innate Pharma insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 0.16% of the stock of Innate Pharma is held by institutions.

    • Read more about Innate Pharma's insider trading history.
    Receive IPHA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

    IPHA Stock News Headlines

    IPHA Innate Pharma S.A. - Seeking Alpha
    Critical AI announcement set to ignite AI 2.0
    A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbling. But for smart traders, this isn’t chaos. It’s opportunity. One veteran trader is revealing how his simple system spots fast setups in moments like this—no guesswork, no complicated strategies, and no big account required.
    See More Headlines

    IPHA Stock Analysis - Frequently Asked Questions

    Innate Pharma's stock was trading at $1.84 at the beginning of 2025. Since then, IPHA stock has increased by 17.9% and is now trading at $2.17.

    Innate Pharma (IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

    Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

    Company Calendar

    Today
    8/08/2025
    Next Earnings (Estimated)
    9/17/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:IPHA
    CIK
    1598599
    Fax
    N/A
    Employees
    220
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $11.00
    Low Price Target
    $11.00
    Potential Upside/Downside
    +414.0%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    2.52
    Current Ratio
    2.60
    Quick Ratio
    2.60

    Sales & Book Value

    Annual Sales
    $21.77 million
    Price / Sales
    9.06
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.11 per share
    Price / Book
    19.45

    Miscellaneous

    Outstanding Shares
    92,180,000
    Free Float
    62,787,000
    Market Cap
    $197.27 million
    Optionable
    Not Optionable
    Beta
    0.22

    Social Links

    The Next 7 Blockbuster Stocks for Growth Investors Cover

    Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

    Get This Free Report

    This page (NASDAQ:IPHA) was last updated on 8/8/2025 by MarketBeat.com Staff
    From Our Partners